---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-011862"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:21:49.358047+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech reports FY2025 net loss of $34.5M, updates PDS0101 Phase 3 with interim PFS endpoint

## Summary
- Net loss of $34.5M ($0.74/share) vs $37.6M ($1.03/share) in 2024; cash $26.7M at year-end.
- Amended VERSATILE-003 Phase 3 protocol to add PFS as interim endpoint; aims for accelerated approval and reduced trial cost.
- PDS01ADC in mCRPC showed median PFS 9.6 months, PSA decline 40% in early NCI-led Phase 2 data.
- New US and Japan patents for PDS0101 extend market protection into 2040s.

## SEC filing metadata
- accession: 0001140361-26-011862
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036126011862/0001140361-26-011862-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036126011862/ef20069202_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-011862
- JSON: https://secwatch.observer/filing/0001140361-26-011862.json
- Plain text: https://secwatch.observer/filing/0001140361-26-011862.txt

## Key facts
- Earnings Releases
  PDS Biotechnology Corp reported the year ended December 31, 2025 results: net income approximately $34.5 million, EPS $0.74 per basic and diluted share.
  - Period: the year ended December 31, 2025
  - Net income: approximately $34.5 million
  - EPS: $0.74 per basic and diluted share
  - Result: reported results
  source text: Full Year 2025 Financial Results Net loss for the year ended December 31, 2025, was approximately $34.5 million, or $0.74 per basic and diluted share, compared to a net loss of $37.6 million, or $1.03 per basic and diluted share for the year ended December 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472091/000114036126011862/0001140361-26-011862-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.